ALNY Summary

  1. NASDAQ
  2. >
  3. ALNY
TickerALNY
DescriptionALNYLAM PHARMACEUTICALS INC
Alnylam Pharmaceuticals Inc. is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam P5x25' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA.
ExchangeNASDAQ
TypeStock
SectorHealthcare
Employees1,453
Next Earnings DateAugust 2nd, 2022
IV131.370903%
IV Percentile99th
IV Rank98.09%
IV Skew8.316068
IV Skew Percentile70th
IV Skew SentimentBearish
Option Volume5,934
Volume568,298
Price$148.25
Previous Close$145.85
52-Week High$212.00
52-Week Low$117.58
50-Day Moving Avg.$133.58
200-Day Moving Avg.$150.49
10-Day Avg. Volume1,075,074
20-Day Avg. Volume1,047,684
30-Day Avg. Volume1,008,380
3-Month Avg. Volume918,904
EPS-$7.49
Outstanding Shares120,813,559
Market Capitalization$17,569,915,900
CurrencyUSD
UpdatedJuly 1st, 2022